Biogen Inc's (NYSE:BIIB) short interest as a percent of float has risen 8.75% since its last report. According to exchange reported data, there are now 5.64 million shares sold short, which is 4.97% of all regular shares that are available for trading. Based on its trading volume, it would take t... Read more
Benzinga - Nov 24
uniQure (NASDAQ:QURE – Get Free Report) and Biogen (NASDAQ:BIIB – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitab... Read more
Markets Daily - Nov 17
Coherent Market Insights has released a report titled "Dementia Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032", which includes market percentage records and a thorough enterprise analysis. This report looks at the market's competition, geographic distribution, ... Read more
Openpr.com - Nov 10
The Central Nervous System Disorders Therapeutics market is estimated to be valued at USD 97,028.1 Mn in 2025 and is expected to reach USD 159,583.2 Mn by 2032, growing at a compound annual growth rate CAGR of 7.4% from 2025 Read more
Openpr.com - Nov 05
Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.In an interview with Bloomberg News, Viehbache... Read more
Benzinga - Aug 13
